Crescent Capital: 3 Key Takeaways for Long-Term Investors
Add-on financings now make up half of Crescent's deal count, a shift that shapes how the firm is working through a slow buyout market.
Three key takeaways emerged from Crescent Capital's recent earnings call on November 10, 2026. First, the company announced a $50 million share repurchase program, authorized by the management team. This move aims to capitalize on the current undervaluation of CCAP shares, which are believed to be trading below the company's net asset value (NAV). Moreover, Sun Life has committed up to $25 million for open-market purchases, further boosting the share repurchase potential.
Second, Crescent Capital is establishing a $150 million joint venture with performing senior loans to reduce the company's leverage ratio and improve return on equity (ROE). This joint venture will utilize asset-based borrowing and $30 million in equity from Crescent Capital itself. Management targets an ROE in the low to mid-teens for this venture, anticipating it to be accretive to gross yield.
Lastly, the firm navigated a market slowdown by directing lending towards existing portfolio companies for growth financing. Direct lending for new leveraged buyouts (LBOs) declined by 60% year-over-year in the third quarter. Despite this, management has focused on providing growth financing to current portfolio companies, with add-on financings accounting for approximately 50% of the company's total deal count and 25% of total dollars committed over the past year.
This strategic approach has helped maintain cash flow stability and strict underwriting standards across their 190 portfolio companies.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
